prognostic impact was independent of clinicopathological and molecular factors (adjusted HR 0.32 95%CI 0.14-0.74, $p=0.0077$).

Conclusion* L1CAM identifies tertiary lymphoid structures with germinal centres. Our data suggest a pivotal role of TLS in the risk of recurrence of EC. L1CAM IHC is simple, available across many study cohorts and could be readily implemented as biomarker of TLS in future trials and clinical care.

486

CLINICOPATHOLOGICAL CHARACTERISTICS OF WOMEN WITH *CTNNB1*-MUTATED ENDOMETRIAL CANCER

^{1,2}J Knez*, ^{1,2}M Sobočan, ³R Kavalir, ⁴M Zupin, ⁴T Buedefeld, ^{4,5}U Potočnik, ^{1,2}J Takač. ¹Maribor University Medical Centre, Division of Gynecology and Perinatology, Maribor, Slovenia; ²UNIVERZA V MARIBORU MEDICINSKA FAKULTETA, Department of Obstetrics and Gynecology, Maribor, Slovenia; ³Maribor University Medical Centre, Department of Pathology, Maribor, Slovenia; ⁴UNIVERZA V MARIBORU MEDICINSKA FAKULTETA, Centre for Human Molecular Genetics and Pharmacogenomics, Maribor, Slovenia; ⁵Faculty of Chemistry and Chemical Engineering, University of Maribor, Maribor, Slovenia

10.1136/ijgc-2021-ESGO.157

Introduction/Background* The molecular characterisation of endometrial cancer (EC) represents a step towards personalised management. The current ESGO-ESTRO-ESP guidelines classify EC into four groups: POLE mutated (POLEmut), p53 abnormal (p53abn), mismatch repair deficient (MMRd) and the largest group of no specific mutational profile (NSMP). Women with NSMP tumours generally have a good prognosis, but if disease recurs, the prognosis tends to be poor. A proposed additional molecular classifier to improve the risk assessment are mutations of catenin beta 1 (*CTNNB1*). The aim of this study was to assess the clinicopathological characteristics of women with *CTNNB1*-mutated tumours for further risk assessment.

Methodology This prospective observational study included women diagnosed with endometrial cancer between January 2020 – March 2021 at the University Medical Centre Maribor, Slovenia. Immunohistochemical (IHC) staining was used to evaluate the expression of p53 and mismatch repair proteins MLH1, MSH2, MSH6 and PMS2. Sanger sequencing of exons 9, 13 and 14 was used to determine the *POLE* status and of exon 3 for *CTNNB1* status. Statistical analysis was performed using IBM SPSS version 23. Descriptive statistics were calculated for numerical variables. Chi-Square (χ^2) test was used to evaluate the relationship between *CTNNB1* status and the tumour stage, depth of tumour invasion and lymph node involvement.

Result(s)* Out of 45 women included in the study, 5 (11.1%) were found to have a mutation in the exon 3 of *CTNNB1*; 2 women in D32V (40%), 2 women in S32C (40%) and 1 woman in S37P (20%). Among them, 4 women (80%) were classified as NSMP and 1 (20%) as p53abn. Moreover, 2 women (40%) were diagnosed with early stage (FIGO I-II) and 3 (60%) with advanced stage (FIGO IIIa or more) EC. *CTNNB1* status was not correlated with lymph-node involvement ($p>.418$) and myometrial ($p>.802$) or lympho-vascular space invasion ($p>.855$).

Conclusion* *CTNNB1* testing could be used for further classification of molecularly undefined EC. Especially in the NSMP group, this could provide more information about the disease biology and lead to better management of women. Further evaluation of the long-term impact of *CTNNB1* mutations on recurrence-free survival and overall survival is needed.

497

ENDOMETRIAL HYPERPLASIA: RISK OF COEXISTENCE AND PROGRESSION TO ENDOMETRIAL CARCINOMA. RETROSPECTIVE COHORT STUDY

¹MDLR Oliver, ¹A Olloqui-Escalona, ¹C González-Macho, ¹C Pérez-Sagaseta, ¹C Guillen-Gamez, ²M Martínez- Lopez, ¹A Tejerizo-García. ¹Hospital Universitario 12 de Octubre, Gynecology Oncology, Madrid, Spain; ²Hospital Universitario 12 de Octubre, Pathology, Madrid, Spain

10.1136/ijgc-2021-ESGO.158

Introduction/Background* Endometrial hyperplasia (EH) is characterized by an irregular proliferation of the endometrial glands with an increased gland/stroma ratio compared to the proliferative endometrium. The risk of malignancy depends on the presence of the atypia. The purpose of this study was to determine incidence of concomitant endometrial carcinoma (EC) and the risk of malignancy of the disease.

Methodology

Retrospective cohort study was performed It includes a total of 120 patients diagnosed of EH by endometrial biopsy at Hospital Universitario 12 de Octubre between January 2015 to January 2020. The epidemiological and clinical characteristics of the patients were analysed. The incidence of concomitant EC was investigated in patients in whom hysterectomy was performed. Also in cases of expectant management and/or medical treatment, the rate of regression, persistence and progression of EH was studied.

Result(s)* According to the criteria of the 2014 WHO classification, 70.8% of cases were EH without atypia and 29.2% with atypia. The mean age at diagnosis was 48.9 years and 71.7% of the patients were premenopausal. The most frequent symptom was abnormal uterine bleeding and the most ultrasound finding was pathological endometrial thickness (52.5%), followed. A suspected endometrial polyp (21.7%). Hysterectomy was performed in 25% of the total cases. In this group of patients, the incidence of concomitant EC was 33.3%, all of them in EH with atypia. In the group of patients with medical or expectant treatment, after a mean follow-up time of 25 months, a regression of the disease was observed in 95.4% and a progression to EC in 2.3%.

Conclusion* Although EH is a benign disease entity, with a high regression-cure rate, its risk of coexistence with EC is not negligible, especially in cases where atypia is observed.

501

LOX1 AND NALP3: FROM IMMUNE TOLERANCE DISRUPTION IN PREGNANCY COMPLICATIONS TO IMMUNE ESCAPE IN ENDOMETRIAL CANCER

¹V Bruno*, ²G Corrado, ³L Ronchetti, ¹B Chiofalo, ⁴M Iacobelli, ⁴A Lobascio, ⁵MA Carosi, ⁶P Nisticò, ³G Piaggio, ¹E Vizza. ¹IRCCS—Regina Elena National Cancer Institute, Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, Rome, Italy; ²Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino, e di Sanità Pubblica, Ginecologia Oncologica, Rome, Italy; ³IRCCS—Regina Elena National Cancer Institute, Department of Research, Diagnosis and Innovative Technologies, UOSD SAFU, Rome, Italy; ⁴IRCCS—Regina Elena National Cancer Institute, Oncofertility Centre, Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, Rome, Italy; ⁵IRCCS—Regina Elena National Cancer Institute, Anatomy Pathology Unit, Department of Research, Diagnosis and Innovative Technologies, Rome, Italy; ⁶IRCCS—Regina Elena National Cancer Institute, Unit of Tumor Immunology and Immunotherapy, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, Rome, Italy

10.1136/ijgc-2021-ESGO.159